RecruitingPhase 4NCT06665971

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

Studying NON RARE IN EUROPE: Eosinophilic esophagitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Diego
Intervention
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT](drug)
Enrollment
30 enrolled
Eligibility
22 years · All sexes
Timeline
20242026

Study locations (1)

Collaborators

Regeneron Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06665971 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Eosinophilic esophagitis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis

← Back to all trials